Xeloda, Capecitabine News

Main Category: Breast Cancer Also Included In: Cancer / Oncology Article Date: 10 Jul 2009 - 1:00 PDT The National Institute for Health and Clinical Excellence announced that, following GlaxoSmithKline's appeal, it will reconsider the submission for Tyverb , a treatment for an aggressive form of advanced breast cancer .1 GSK is pleased that NICE's ...

Purpose:To identify new polymorphisms in DNA repair pathways that are associated with efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced colorectal cancer .Methods:We studied progression-free survival in 91 ACC patients, of whom germ-line DNA was isolated and genotyped using an Asper Biotech array.

Standard adjuvant chemotherapy was superior to capecitabine for treating older women with early breast cancer, although with substantial toxicity.

One patient was held by US immigration officials for four hours before they allowed him to enter the country.

A 62 year old Singapore man, who was trying to enter the U.S., was detained at customs for several hours for an odd reason - he had no fingerprints! Even more disturbing is that the cause of his fingerprint loss was due to taking a common cancer drug, capecitabine, also known as Xeloda by its trade name.

Patients taking a commonly prescribed cancer drug may draw extra scrutiny from U.S. immigration authorities because a side effect can make their fingerprints invisible to scanners, Singapore oncologists said.

Data presented at the American Society of Clinical Oncology 2009 meeting, in Orlando, Florida, show that bevacizumab plus commonly used chemotherapies increases the chance of the patient living without the disease worsening by up to 36% compared to chemotherapies alone, in women receiving first-line therapy for advanced HER2-negative breast cancer.

Data from the ToGA study presented at the American Society for Clinical Oncology Annual Meeting in Orlando, Florida showed that adding trastuzumab to standard chemotherapy prolongs the lives of patients with this aggressive cancer on average by nearly 2.7 months to 13.8 months, a 26% increase in survival.

Keryx Biopharmaceuticals, Inc. yesterday announced data on the clinical activity of KRX-0401 , the Company's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer.

According to CNN.com, the drug capecitabine, which is marketed in the US as Xeloda and used to treat cancer patients following chemotherapy, has a just-discovered side effect: depleting fingerprints.

Genentech, Inc. today announced results of a Phase III study that showed Avastin plus commonly used chemotherapies, including capecitabine and anthracycline-based therapies, increased the time women receiving first-line therapy for advanced HER2-negative breast cancer lived without the disease worsening , compared to the chemotherapies alone.

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 in the Treatment of Advanced Metastatic Colon Cancer NEW YORK, May 31 NY-Keryx-0401-phase2 KRX-0401 + Capecitabine More Than Doubled Time to Progression and Overall Response Rate as well as Extended Overall ...

ZIOPHARM Oncology, Inc. announced today that it presented positive data from both a Phase Ib clinical trial and preclinical dosing studies of orally administered indibulin , the Company's novel tubulin binding agent, at the 45th Annual American Society of Clinical Oncology meeting held in Orlando, FL, May 29th to June 2nd.

So where did this Sci-Fi and mystery novelist's dream come from? It was discovered at the airport.

A cancer patient was detained for hours on a trip to the United States because his treatment caused him to lose his fingerprints.

Women living with HER2 positive breast cancer now have a new treatment option for the first time in almost ten years.

Before they can enter the USA, virtually all non-U.S. citizens 14 to 79 have their fingerprints screened at the airport or seaport to confirm their identity and make sure they're not a security threat.

A Singaporean man trying to enter the U.S. was detained by TSA officials for four hours as a possible security threat, all because he had no fingerprints.

Department of Homeland Security Officer Brian Pittack stands at his station with a 10-fingerprint scanner for international arriving passengers at Dulles International Airport in Dulles, Virginia.

US immigration officials detained a man at an airport for four hours after customs checks revealed he had no fingerprints.